213 related articles for article (PubMed ID: 24817413)
1. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
Talavera Pons S; Lamblin G; Boyer A; Sautou V; Abergel A
Eur J Clin Pharmacol; 2014 Jul; 70(7):775-89. PubMed ID: 24817413
[TBL] [Abstract][Full Text] [Related]
2. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Wilby KJ; Partovi N; Ford JA; Greanya E; Yoshida EM
Can J Gastroenterol; 2012 Apr; 26(4):205-10. PubMed ID: 22506260
[TBL] [Abstract][Full Text] [Related]
3. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
4. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
5. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
Wilby KJ; Greanya ED; Ford JA; Yoshida EM; Partovi N
Ann Hepatol; 2012; 11(2):179-85. PubMed ID: 22345334
[TBL] [Abstract][Full Text] [Related]
6. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Wire MB; Fang L; Hussaini A; Kleha JF; Theodore D
Antimicrob Agents Chemother; 2014 Nov; 58(11):6704-9. PubMed ID: 25155600
[TBL] [Abstract][Full Text] [Related]
7. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
8. The importance of drug-drug interactions in the DAA era.
Back D; Else L
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S343-8. PubMed ID: 24091114
[TBL] [Abstract][Full Text] [Related]
9. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
10. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
12. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
13. [Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].
Nikitin AV
Antibiot Khimioter; 2012; 57(9-10):47-9. PubMed ID: 23477220
[No Abstract] [Full Text] [Related]
14. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
Talavera Pons S; Boyer A; Lamblin G; Chennell P; Châtenet FT; Nicolas C; Sautou V; Abergel A
Br J Clin Pharmacol; 2017 Feb; 83(2):269-293. PubMed ID: 27530469
[TBL] [Abstract][Full Text] [Related]
15. [Systematic review of new protease inhibitors interactions: telaprevir and boceprevir].
Izquierdo-García E; Escobar-Rodríguez I
Farm Hosp; 2012; 36(6):469-82. PubMed ID: 23461440
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Coilly A; Dumortier J; Botta-Fridlund D; Latournerie M; Leroy V; Pageaux GP; Agostini H; Giostra E; Moreno C; Roche B; Antonini TM; Guillaud O; Lebray P; Radenne S; Saouli AC; Calmus Y; Alric L; Debette-Gratien M; De Ledinghen V; Durand F; Duvoux C; Samuel D; Duclos-Vallée JC
PLoS One; 2015; 10(9):e0138091. PubMed ID: 26394142
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
Rivero-Juarez A; Camacho A; Rivero A
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1157-65. PubMed ID: 26004270
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
19. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].
Delaborde L; Logerot S; Fonrose X
Therapie; 2014; 69(6):491-7. PubMed ID: 25320939
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.
Backus LI; Belperio PS; Shahoumian TA; Cheung R; Mole LA
Aliment Pharmacol Ther; 2014 Jan; 39(1):93-103. PubMed ID: 24206566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
